DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,200 filers reported holding DANAHER CORPORATION in Q1 2018. The put-call ratio across all filers is 0.54 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2017 | $3,000 | +50.0% | 27 | 0.0% | 0.00% | – |
Q3 2017 | $2,000 | 0.0% | 27 | 0.0% | 0.00% | – |
Q2 2017 | $2,000 | -99.8% | 27 | -99.8% | 0.00% | -100.0% |
Q4 2016 | $890,000 | -55.1% | 11,435 | -54.8% | 0.02% | -55.8% |
Q3 2016 | $1,984,000 | -24.0% | 25,315 | -2.1% | 0.05% | -24.6% |
Q2 2016 | $2,612,000 | +2.1% | 25,865 | -4.1% | 0.07% | +46.8% |
Q1 2016 | $2,558,000 | +144.8% | 26,965 | +139.7% | 0.05% | +135.0% |
Q4 2015 | $1,045,000 | +4.8% | 11,249 | -3.8% | 0.02% | +5.3% |
Q3 2015 | $997,000 | -83.3% | 11,699 | -83.2% | 0.02% | -82.6% |
Q2 2015 | $5,975,000 | -0.2% | 69,810 | -1.0% | 0.11% | +4.8% |
Q1 2015 | $5,986,000 | -33.1% | 70,510 | -32.5% | 0.10% | -30.2% |
Q4 2014 | $8,951,000 | +9.0% | 104,435 | -3.4% | 0.15% | +4.2% |
Q3 2014 | $8,214,000 | -18.1% | 108,110 | -15.1% | 0.14% | -16.4% |
Q2 2014 | $10,029,000 | +0.5% | 127,380 | -4.3% | 0.17% | -2.3% |
Q1 2014 | $9,983,000 | -15.3% | 133,110 | -12.8% | 0.18% | -16.7% |
Q4 2013 | $11,785,000 | +5.6% | 152,660 | -5.1% | 0.21% | -1.9% |
Q3 2013 | $11,155,000 | +19.2% | 160,925 | +8.8% | 0.21% | +13.2% |
Q2 2013 | $9,362,000 | – | 147,900 | – | 0.19% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |